Year: 2026

GROUP CEO’S REVIEW Rait Riim, CEO and Member of the Management Board of Arco Vara AS: “The first quarter of 2026 developed largely as expected for Arco Vara, with the company maintaining its focus on advancing its ongoing development projects. During the quarter, a change also occurred in the company’s management, and as of 1 April, I have assumed the role of Chief Executive Officer of Arco Vara. I have more than 20 years of experience in the real estate sector and joining Arco Vara represents an opportunity for me to contribute to the company’s next phase of development. Arco Vara’s ambition is to be a real estate developer recognized as a benchmark for urban space and living environment quality, sustainability, and long-term value creation. It is important that a developer does not merely construct buildings but creates holistic environments...

OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1 €22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, respectively Unchanged cash runway until early Q4 2026 Filing of the 2025 Universal Registration Document is postponed to no later than May 28, 2026NANTES, France, April 30, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the “Company”), today reported its full year 2025 unaudited consolidated financial results, as approved by the Board of Directors on April 29, 2026. Audit procedures by the Company’s statutory auditors on the Company’s 2025 consolidated financial statements are still ongoing. Full Year 2025 Consolidated Financial Results (IFRS, unaudited)     In million...

Press ReleaseNicox Provides Full Year 2025 Financial Results and Corporate UpdateRevenue of €16.8 million (€7.9 million in 2024) Net loss significantly reduced to €2.4 million (€22.4 million in 2024) NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone payment Regulatory milestones anticipated to extend cash runway beyond 2027April 30, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced its financial results for the full year of 2025, as approved by the Board of Directors on 29 April 2026, and provided an update on key future milestones. “2025 marked a pivotal turning point for Nicox,” said Gavin Spencer, Chief Executive Officer of Nicox. “We have significantly...

NET INCOME GROUP SHARE OF EUR 266 MILLION, UP 21.2% VS. Q1 2025  RETURN ON TANGIBLE EQUITY (ROTE) AT 13.9% VS. 11.0% IN Q1 2025EPS1 AT EUR 0.31 UP 29% VS. Q1 2025 Q1 2026 RESULTS2 Leasing and Services margins at EUR 757 million, up 6.9% vs. Q1 2025 Underlying margins3 at 587 bps of average earning assets vs. 562 bps in Q1 2025 Net Used Car Sales result4 at EUR 59 million down 46.9% vs. Q1 2025 Gross UCS result per unit5 at EUR 470, in line with 2026 guidance Synergies6 at EUR 110 million, up from EUR 61 million in Q1 2025, on track to achieve PowerUP 2026 target of EUR 440 million for full year 2026 Cost to income ratio7 at 54.0%, down 4 percentage points vs. 58.0% in Q1 2025 Earning assets8 at EUR 52.5 billion, -1.8% vs. March 2025 CET1 ratio at 13.9% as at end March 2026 “Ayvens delivered once again a strong set of financial results...

Inbank started 2026 with strong sales growth and stable underlying performance, while profitability development was more moderate. In Q1 2026 Inbank earned a consolidated net profit of €4 million, decreasing 11% year-on-year. The return on equity (ROE) in Q1 was 9.4%.In Q1 2026, Inbank’s total net income amounted to €21.9 million, increasing 5% year-on-year. Operating expenses increased to €12.1 million, reflecting higher continued investments in technology and marketing spend, while remaining stable compared to the previous quarters. Originated volume reached €206 million, increasing 24% year-on-year and marking a record quarterly result. Regionally growth was led by Central and Eastern Europe, where originated volume increased by 33%, while the Baltics also delivered solid growth of 18%. Sales growth was broad-based across most product...